With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	1.31
Equity-to-Asset	0.3
Debt-to-Equity	0.47
Debt-to-EBITDA	0.41
Interest Coverage	50.24
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	7.75	Distress Grey Safe
Beneish M-Score	-2.6	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	24
	3-Year EBITDA Growth Rate	26.3
	3-Year EPS without NRI Growth Rate	26
	3-Year FCF Growth Rate	34.6
	3-Year Book Growth Rate	21.1
	Future 3-5Y EPS without NRI Growth Rate	22.84
	Future 3-5Y Total Revenue Growth Rate	20.44

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	23.03
	9-Day RSI	26.24
	14-Day RSI	29.9
	6-1 Month Momentum %	-23.99
	12-1 Month Momentum %	8.03

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.94
	Quick Ratio	0.75
	Cash Ratio	0.36
	Days Inventory	297.62
	Days Sales Outstanding	82.08
	Days Payable	197.93

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.59
	Dividend Payout Ratio	0.47
	3-Year Dividend Growth Rate	18.1
	Forward Dividend Yield %	1.59
	5-Year Yield-on-Cost %	2.8
	3-Year Average Share Buyback Ratio	1.7
	Shareholder Yield %	1.57

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	84.66
	Operating Margin %	43.75
	Net Margin %	35.01
	FCF Margin %	24.77
	ROE %	89.11
	ROA %	28.19
	ROIC %	28.4
	ROC (Joel Greenblatt) %	121.5
	ROCE %	78.33
	Years of Profitability over Past 10-Year	10

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	27.79
	Forward PE Ratio	22.14
	PE Ratio without NRI	27.79
	Shiller PE Ratio	50.69
	Price-to-Owner-Earnings	27.67
	PEG Ratio	1.59
	PS Ratio	9.73
	PB Ratio	21.76
	Price-to-Tangible-Book	41.95
	Price-to-Free-Cash-Flow	39.23
	Price-to-Operating-Cash-Flow	22.25
	EV-to-EBIT	22.59
	EV-to-Forward-EBIT	17.55
	EV-to-EBITDA	19.83
	EV-to-Forward-EBITDA	16.08
	EV-to-Revenue	10.15
	EV-to-Forward-Revenue	8.08
	EV-to-FCF	38.77
	Price-to-Projected-FCF	3.12
	Price-to-DCF (Earnings Based)	1.37
	Price-to-DCF (FCF Based)	1.98
	Price-to-Median-PS-Value	1.21
	Price-to-Peter-Lynch-Fair-Value	1.31
	Price-to-Graham-Number	7.4
	Earnings Yield (Greenblatt) %	4.43
	FCF Yield %	2.56
	Forward Rate of Return (Yacktman) %	22.14

Financials (Next Earnings Date:2025-02-05)

Annual Quarterly TTM

OCSE:NOVO B's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Novo Nordisk AS Executives

Details

GF Value: kr849.64

OCSE:NOVO B

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with NOVO B. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil kr)	270,583
	EPS (TTM) (kr)	21.2
	Beta	1.14
	Volatility %	26.84
	14-Day RSI	29.9
	14-Day ATR (kr)	38.48683
	20-Day SMA (kr)	753.455
	12-1 Month Momentum %	8.03
	52-Week Range (kr)	526 - 1033.2
	Shares Outstanding (Mil)	4,441.34

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Novo Nordisk AS Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Novo Nordisk AS Stock Events

Financials Calendars

	Event	Date	Price(kr)
No Event Data

Novo Nordisk AS Frequently Asked Questions

What is Novo Nordisk AS(OCSE:NOVO B)'s stock price today?

The current price of OCSE:NOVO B is kr622.60. The 52 week high of OCSE:NOVO B is kr1033.20 and 52 week low is kr526.00.

When is next earnings date of Novo Nordisk AS(OCSE:NOVO B)?

The next earnings date of Novo Nordisk AS(OCSE:NOVO B) is 2025-02-05.

Does Novo Nordisk AS(OCSE:NOVO B) pay dividends? If so, how much?

The Dividend Yield % of Novo Nordisk AS(OCSE:NOVO B) is 1.59% (As of Today), Highest Dividend Payout Ratio of Novo Nordisk AS(OCSE:NOVO B) was 0.62. The lowest was 0.33. And the median was 0.46. The Forward Dividend Yield % of Novo Nordisk AS(OCSE:NOVO B) is 1.59%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.